Terapia del linfoma primitivo del sistema nervoso centrale

Recenti progressi

Translated title of the contribution: Treatment of primary central nervous systemlymphoma. Recent advances

Marco Foppoli, Andrés J M Ferreri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Primary central nervous system lymphoma is a quite infrequent disease within lymphoproliferative disorders. Moreover, it must be taken into account that, even considering the progressive spreading of ameliorated diagnostic tools and skills, histology remains the hinge of a correct diagnosis (stereotactic cerebral biopsy). Hence, randomised clinical protocols with a sufficiently large number of patients enrolled are difficult to perform and a generalized consensus on the best therapeutic options is hard to achieve. In this article, the more frequent practical and clinical aspects regarding diagnosis and staging of this rare disease are discussed. Furthermore, we analyze the different therapeutic options that were considered in a relatively recent past in which the median survival from diagnosis was not longer than a year, working down the pathway to the present and, finally, to the near future, always considering both first line and salvage therapy. The goal remains to optimize and standardize the therapeutic approach in order to achieve a generalized consensus that should lead to better overall clinical results.

Original languageItalian
Pages (from-to)376-380
Number of pages5
JournalRecenti Progressi in Medicina
Volume101
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Salvage Therapy
Lymphoproliferative Disorders
Clinical Protocols
Rare Diseases
Lymphoma
Histology
Therapeutics
Central Nervous System
Biopsy
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Terapia del linfoma primitivo del sistema nervoso centrale : Recenti progressi. / Foppoli, Marco; Ferreri, Andrés J M.

In: Recenti Progressi in Medicina, Vol. 101, No. 10, 10.2010, p. 376-380.

Research output: Contribution to journalArticle

@article{5e3972f9d971489a8b8dfaef3408eabe,
title = "Terapia del linfoma primitivo del sistema nervoso centrale: Recenti progressi",
abstract = "Primary central nervous system lymphoma is a quite infrequent disease within lymphoproliferative disorders. Moreover, it must be taken into account that, even considering the progressive spreading of ameliorated diagnostic tools and skills, histology remains the hinge of a correct diagnosis (stereotactic cerebral biopsy). Hence, randomised clinical protocols with a sufficiently large number of patients enrolled are difficult to perform and a generalized consensus on the best therapeutic options is hard to achieve. In this article, the more frequent practical and clinical aspects regarding diagnosis and staging of this rare disease are discussed. Furthermore, we analyze the different therapeutic options that were considered in a relatively recent past in which the median survival from diagnosis was not longer than a year, working down the pathway to the present and, finally, to the near future, always considering both first line and salvage therapy. The goal remains to optimize and standardize the therapeutic approach in order to achieve a generalized consensus that should lead to better overall clinical results.",
keywords = "Autologous stem cells transplant, Cytarabin, Methotrexate, Primary central nervous system lymphoma",
author = "Marco Foppoli and Ferreri, {Andr{\'e}s J M}",
year = "2010",
month = "10",
doi = "10.1701/519.6215",
language = "Italian",
volume = "101",
pages = "376--380",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "10",

}

TY - JOUR

T1 - Terapia del linfoma primitivo del sistema nervoso centrale

T2 - Recenti progressi

AU - Foppoli, Marco

AU - Ferreri, Andrés J M

PY - 2010/10

Y1 - 2010/10

N2 - Primary central nervous system lymphoma is a quite infrequent disease within lymphoproliferative disorders. Moreover, it must be taken into account that, even considering the progressive spreading of ameliorated diagnostic tools and skills, histology remains the hinge of a correct diagnosis (stereotactic cerebral biopsy). Hence, randomised clinical protocols with a sufficiently large number of patients enrolled are difficult to perform and a generalized consensus on the best therapeutic options is hard to achieve. In this article, the more frequent practical and clinical aspects regarding diagnosis and staging of this rare disease are discussed. Furthermore, we analyze the different therapeutic options that were considered in a relatively recent past in which the median survival from diagnosis was not longer than a year, working down the pathway to the present and, finally, to the near future, always considering both first line and salvage therapy. The goal remains to optimize and standardize the therapeutic approach in order to achieve a generalized consensus that should lead to better overall clinical results.

AB - Primary central nervous system lymphoma is a quite infrequent disease within lymphoproliferative disorders. Moreover, it must be taken into account that, even considering the progressive spreading of ameliorated diagnostic tools and skills, histology remains the hinge of a correct diagnosis (stereotactic cerebral biopsy). Hence, randomised clinical protocols with a sufficiently large number of patients enrolled are difficult to perform and a generalized consensus on the best therapeutic options is hard to achieve. In this article, the more frequent practical and clinical aspects regarding diagnosis and staging of this rare disease are discussed. Furthermore, we analyze the different therapeutic options that were considered in a relatively recent past in which the median survival from diagnosis was not longer than a year, working down the pathway to the present and, finally, to the near future, always considering both first line and salvage therapy. The goal remains to optimize and standardize the therapeutic approach in order to achieve a generalized consensus that should lead to better overall clinical results.

KW - Autologous stem cells transplant

KW - Cytarabin

KW - Methotrexate

KW - Primary central nervous system lymphoma

UR - http://www.scopus.com/inward/record.url?scp=77958593098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958593098&partnerID=8YFLogxK

U2 - 10.1701/519.6215

DO - 10.1701/519.6215

M3 - Articolo

VL - 101

SP - 376

EP - 380

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 10

ER -